Edgewise Therapeutics Stock Performance
| EWTX Stock | USD 26.43 0.76 2.96% |
The firm shows a Beta (market volatility) of 1.54, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Edgewise Therapeutics will likely underperform. At this point, Edgewise Therapeutics has a negative expected return of -0.21%. Please make sure to confirm Edgewise Therapeutics' mean deviation, treynor ratio, as well as the relationship between the Treynor Ratio and daily balance of power , to decide if Edgewise Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Edgewise Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of conflicting performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return 2.67 | Five Day Return (4.27) | Year To Date Return (2.50) | Ten Year Return (12.15) | All Time Return (12.15) |
1 | Edgewise Therapeutics Announces Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten in Individuals with Becker Muscular Dystrophy | 12/16/2024 |
2 | Disposition of 1729 shares by Semigran Marc of Edgewise Therapeutics at 30.0803 subject to Rule 16b-3 | 12/24/2024 |
3 | Disposition of 100000 shares by Alan Russell of Edgewise Therapeutics at 27.3747 subject to Rule 16b-3 | 12/30/2024 |
4 | Disposition of 24960 shares by Carruthers R Michael of Edgewise Therapeutics at 28.5862 subject to Rule 16b-3 | 01/03/2025 |
5 | Insider Trading | 01/21/2025 |
6 | Edgewise Therapeutics Strengthens Leadership Team, Appoints Merck Veteran as Chief Development Officer - StockTitan | 01/22/2025 |
7 | Disposition of 25000 shares by Donovan Joanne M. of Edgewise Therapeutics at 27.6263 subject to Rule 16b-3 | 01/28/2025 |
8 | Disposition of 10000 shares by Behrad Derakhshan of Edgewise Therapeutics at 30.03 subject to Rule 16b-3 | 02/05/2025 |
9 | Disposition of 900 shares by Kevin Koch of Edgewise Therapeutics at 31.1311 subject to Rule 16b-3 | 02/06/2025 |
10 | Edgewise Therapeutics CEO Kevin Koch sells 287,315 in stock - MSN | 02/10/2025 |
11 | Janus Henderson Group PLC Expands Stake in Edgewise Therapeutics Inc | 02/14/2025 |
12 | Should You Invest in Edgewise Therapeutics | 02/19/2025 |
13 | Edgewise Therapeutics Trading 5.9 percent Higher - Should You Buy - MarketBeat | 02/24/2025 |
14 | Edgewise Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights | 03/03/2025 |
15 | Decoding Edgewise Therapeutics Inc A Strategic SWOT Insight | 03/04/2025 |
16 | Edgewise Therapeutics More Expensive Now, But Much More Derisked - Seeking Alpha | 03/10/2025 |
17 | Acquisition by Donovan Joanne M. of 138750 shares of Edgewise Therapeutics at 17.05 subject to Rule 16b-3 | 03/13/2025 |
| Begin Period Cash Flow | 86.1 M | |
| Free Cash Flow | -110.3 M |
Edgewise |
Edgewise Therapeutics Relative Risk vs. Return Landscape
If you would invest 3,017 in Edgewise Therapeutics on December 17, 2024 and sell it today you would lose (450.00) from holding Edgewise Therapeutics or give up 14.92% of portfolio value over 90 days. Edgewise Therapeutics is currently does not generate positive expected returns and assumes 3.5056% risk (volatility on return distribution) over the 90 days horizon. In different words, 31% of stocks are less volatile than Edgewise, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Edgewise Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Edgewise Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Edgewise Therapeutics, and traders can use it to determine the average amount a Edgewise Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0594
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | EWTX |
Estimated Market Risk
| 3.51 actual daily | 31 69% of assets are more volatile |
Expected Return
| -0.21 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.06 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Edgewise Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Edgewise Therapeutics by adding Edgewise Therapeutics to a well-diversified portfolio.
Edgewise Therapeutics Fundamentals Growth
Edgewise Stock prices reflect investors' perceptions of the future prospects and financial health of Edgewise Therapeutics, and Edgewise Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Edgewise Stock performance.
| Return On Equity | -0.34 | ||||
| Return On Asset | -0.24 | ||||
| Current Valuation | 1.98 B | ||||
| Shares Outstanding | 95.21 M | ||||
| Price To Earning | 3.45 X | ||||
| Price To Book | 5.32 X | ||||
| EBITDA | (158.83 M) | ||||
| Net Income | (133.81 M) | ||||
| Cash And Equivalents | 248.4 M | ||||
| Cash Per Share | 4.99 X | ||||
| Total Debt | 4.74 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 27.49 X | ||||
| Book Value Per Share | 4.84 X | ||||
| Cash Flow From Operations | (109.03 M) | ||||
| Earnings Per Share | (1.45) X | ||||
| Market Capitalization | 2.44 B | ||||
| Total Asset | 486.82 M | ||||
| Retained Earnings | (378.58 M) | ||||
| Working Capital | 451.62 M | ||||
About Edgewise Therapeutics Performance
Evaluating Edgewise Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Edgewise Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Edgewise Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.27) | (0.29) | |
| Return On Capital Employed | (0.34) | (0.36) | |
| Return On Assets | (0.27) | (0.29) | |
| Return On Equity | (0.29) | (0.28) |
Things to note about Edgewise Therapeutics performance evaluation
Checking the ongoing alerts about Edgewise Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Edgewise Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Edgewise Therapeutics generated a negative expected return over the last 90 days | |
| Edgewise Therapeutics has high historical volatility and very poor performance | |
| Edgewise Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (133.81 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Edgewise Therapeutics currently holds about 248.4 M in cash with (109.03 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.99. | |
| Edgewise Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Over 100.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Acquisition by Donovan Joanne M. of 138750 shares of Edgewise Therapeutics at 17.05 subject to Rule 16b-3 |
- Analyzing Edgewise Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Edgewise Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Edgewise Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Edgewise Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Edgewise Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Edgewise Therapeutics' stock. These opinions can provide insight into Edgewise Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Edgewise Stock Analysis
When running Edgewise Therapeutics' price analysis, check to measure Edgewise Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edgewise Therapeutics is operating at the current time. Most of Edgewise Therapeutics' value examination focuses on studying past and present price action to predict the probability of Edgewise Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edgewise Therapeutics' price. Additionally, you may evaluate how the addition of Edgewise Therapeutics to your portfolios can decrease your overall portfolio volatility.